The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Results of this phase III trial could change the current standard of care for treating nonseminomatous or combined germ cell tumors of the testis.
The study found that patients who were randomized to receive avelumab and best supportive care lived significantly longer than those who only received best supportive care.
Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results.
A new study used two patient-reported measures of sexual function following radical prostatectomy to assess sexual interest and satisfaction in men with prostate cancer.
Researchers compared several glucocorticoid regimens, given in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer.
In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.
The PAIREDCAP trial looked at different biopsy approaches to see which has the highest cancer detection rate for prostate cancer.